BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Most Vital Crossroads in Olympic History - 2The most effective method to Oversee Unsold SUVs in the Car Business
- 3What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- 4Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- 56 Top Computer game Control center
- Find Your Ideal Tea: Six Particular Assortments
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Most loved Well known Accessory Styles For 2024
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Hanwha Ocean secures orders worth $866m for five vessels
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Putting resources into Yourself: Self-awareness Techniques
- Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
